作者
Laura Marandino, Emmanuele De Luca, Clizia Zichi, Pasquale Lombardi, Maria Lucia Reale, Daniele Pignataro, Rosario F Di Stefano, Eleonora Ghisoni, Annapaola Mariniello, Elena Trevisi, Gianmarco Leone, Leonardo Muratori, Anna La Salvia, Cristina Sonetto, Consuelo Buttigliero, Marcello Tucci, Massimo Aglietta, Silvia Novello, Giorgio V Scagliotti, Francesco Perrone, Massimo Di Maio
发表日期
2019/10/1
来源
Clinical Genitourinary Cancer
卷号
17
期号
5
页码范围
332-347. e2
出版商
Elsevier
简介
Quality of life (QoL) is not included among the end points in many studies, and QoL results are underreported in many phase 3 oncology trials. We performed a systematic review to describe QoL prevalence and heterogeneity in QoL reporting in recently published prostate cancer phase 3 trials. A PubMed search was performed to identify primary publications of randomized phase 3 trials testing anticancer drugs in prostate cancer, issued between 2012 and 2018. We analyzed QoL inclusion among end points, presence of QoL results, and methodology of QoL analysis. Seventy-two publications were identified (15 early-stage, 20 advanced hormone-sensitive, and 37 castration-resistant prostate cancer [CRPC]). QoL was not listed among study end points in 23 studies (31.9%) (40.0% early stage, 40.0% advanced hormone sensitive, and 24.3% CRPC). QoL results were absent in 15 (30.6%) of 49 primary …
学术搜索中的文章
L Marandino, E De Luca, C Zichi, P Lombardi… - Clinical Genitourinary Cancer, 2019
